Retevmo (selpercatinib) — Medica
Histiocytic neoplasm (Langerhans cell histiocytosis, Erdheim-Chester disease, or Rosai-Dorfman disease), RET fusion-positive
Initial criteria
- Patient is age ≥ 18 years
- Patient has ONE of the following: Langerhans cell histiocytosis; OR Erdheim-Chester disease; OR Rosai-Dorfman disease
- Patient has a rearranged during transfection (RET) fusion
Approval duration
1 year